Monoclonal antibodies for detection of viral capsids and gene therapy research

­Summary
The current technology is a series of monoclonal antibodies against AAVAnc80 capsids for gene therapy research.

Technology Overview
Detection and neutralization of viral capsids are needed to advance gene therapy research, but to date, no antibodies exist that can exclusively detect fully assembled AAVAnc80 capsids and not other serotype capsids.    OHSU researchers have developed a set of novel monoclonal antibodies against AAVAnc80 capsids, including:

• Antibodies that recognize the fully-assembled AAVAnc80 capsids.
• Antibodies that recognize both fully-assembled AAVAnc80 capsids and monomers of AAVAnc80 capsids.
• Antibodies with and without the ability to neutralize AAVAnc80 vectors.
• Antibodies against AAVAnc80 capsids that do not recognize AAV2, AAV5 or AAV9 capsids.

Licensing Opportunity
These biological materials available for licensing.